📊 Analyst Consensus & Targets
- Analyst Rating: Buy
- Price Target: $491.91666
- Sector: Healthcare – Biotechnology
💡 The Growth Thesis
Buy Consensus: Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). Analysts project a 8.5% potential upside. Currently trading at a Forward P/E of 22.401722.